CareDx, Inc Q4 2025 Earnings Call Summary

Testing services growth of 23% was driven by a layering effect of kidney centers restarting surveillance protocols and expanded for-cause utilization.

The solution selling strategy successfully integrated digital and pharmacy offerings, resulting in 47% year-over-year growth for Patient and Digital Solutions.

Revenue Cycle Management (RCM) transitioned from stabilization to a core strength, reducing claim rejection rates by over 60% through automation and AI deployment.

The Lab Products segment benefited from a global market transition toward NGS-based HLA typing, where the company maintains a leadership position.

Strategic infrastructure investments, specifically the Epic Aura integration, are designed to reduce clinical friction and improve electronic order data quality.

Clinical evidence generation remains the foundation for adoption, highlighted by SHORE registry data demonstrating HeartCare’s prognostic value beyond traditional biopsy.

Management emphasized a disciplined capital allocation strategy, returning capital via share repurchases while maintaining a debt-free balance sheet with $200,000,000 in cash.

Full year 2026 revenue guidance of $420,000,000 to $444,000,000 assumes a $7,500,000 headwind from the anticipated midyear finalization of the Medicare LCD.

The ‘Transplant Plus’ strategy focuses on the 2026 CLIA readiness of Allaheme, targeting commercial introduction into the cell therapy market by early 2027.

Operational guidance includes a $10,000,000 investment in enterprise systems, including an 18-month migration to Epic Enterprise LIMS to streamline multi-site data exchange.

Volume guidance of 12% growth at the midpoint is characterized as conservative, excluding potential procedural volume increases or immediate lift from new Epic integrations.

Management targets a long-term 20% adjusted EBITDA margin, supported by a 50% flow-through of incremental gross profit dollars to the bottom line.

A pricing reset for AlloSure Kidney went into effect on 01/01/2026, reducing reimbursement by 4% from $2,841 to $2,753 via a new PLA code.

The company implemented a one-time $6,700,000 cash bonus for nonexecutives in lieu of equity to manage shareholder dilution and normalize the employee burn rate.

Management transition announced with Keith Kennedy assuming the dual role of COO and CFO following the departure of Nathan Smith.

The anticipated Medicare LCD remains a primary variable, with guidance modeling a scenario where only one test per date of service is reimbursed for heart transplants.